Influenza research

SARS-CoV-2 vaccination creates a strong, persistent T-cell response

Retrieved on: 
Thursday, December 23, 2021
Blood, University of Melbourne, Center, Vaccination, University of Rochester Medical Center, Omicron, St. Jude Children's Research Hospital, NCI-designated Cancer Center, Immunity, NHMRC, National, Washington University in St. Louis, ALSAC, University, Survival, National Institute of Allergy and Infectious Diseases, COVID-19, Research, Australian Research Council, Hospital, National Cancer Center, Immune system, Awareness, Child, Lymph, Social media, Monash University, Severe acute respiratory syndrome coronavirus 2, CD4, Multimedia, National Institute, National Cancer Institute, Excellence, Influenza research, Infection, Contract, Vaccine, Jude the Apostle, Cell

The findings suggest that some aspects of the immune response to mRNA vaccines remain robust six months after vaccination.

Key Points: 
  • The findings suggest that some aspects of the immune response to mRNA vaccines remain robust six months after vaccination.
  • Much of the research on immune response to mRNA vaccination has focused on antibody levels, which can be measured by a blood test.
  • Researchers wanted to better understand the specificity and structure of the T-cell response to vaccination.
  • The cohort was established in 2020 with hospital St. Jude employees who volunteered to have their immune response to SARS-CoV-2 infection and vaccination monitored.

U.S. Influenza (Flu) Vaccines Market Report 2021: Growth, Demand, Trends, Opportunity & Forecasts, 2015-2020 & 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Health, Pharmaceutical, Vaccines, Medical specialties, Clinical medicine, Medicine, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Influenza A virus subtype H1N1, Influenza research, Influenza A virus subtype H5N1

The United States influenza vaccines market size to cross US$ 5.5 Billion by 2028.

Key Points: 
  • The United States influenza vaccines market size to cross US$ 5.5 Billion by 2028.
  • This new market report presents an inclusive study of the entire United States influenza vaccines market.
  • The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States influenza vaccines market.
  • What is the total market size and forecast (until 2028) for the U.S. influenza vaccines market?

Global Avian Influenza Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 30, 2021
Infectious diseases, Health, Clinical trials, Health sciences, Health, Clinical research, Pharmaceutical industry, Drug discovery, Agricultural health and safety, Animal virology, Avian influenza, Clinical trial, Influenza, Influenza pandemic, Influenza research

The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Avian Influenza Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Avian Influenza market.
  • It covers emerging therapies for Avian Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Avian Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Mexico's Government, Direct Relief Transport Polio Vaccine to Ecuador in Response to International Appeal

Retrieved on: 
Wednesday, March 17, 2021
Medical specialties, Polio, Medicine, Clinical medicine, Vaccines, Vaccination, Vaccine, Influenza research, Pulse Polio

Ecuador last month launched a national campaign to inoculate infants against polio, but it ran short of the vaccine doses needed.

Key Points: 
  • Ecuador last month launched a national campaign to inoculate infants against polio, but it ran short of the vaccine doses needed.
  • Ecuador's Ministry of Public Health issued an international appeal for polio vaccine to organizations including Direct Relief and nations including Mexico.
  • Ecuador requested 95,000 doses of the polio vaccine and 138,000 doses of other vaccines commonly given to children.
  • The Government of Mexico responded to the appeal, offering to donate the polio vaccine from its stockpile at the national vaccine agency BIRMEX.

AHF: Vaccine Hoarding by Rich Countries Stokes the Pandemic

Retrieved on: 
Wednesday, March 17, 2021
White House, Federal Government, Public policy, Government, Health, Public policy, Infectious diseases, General Health, Pharmaceutical, Medical specialties, Vaccines, Medicine, Vaccination, Vaccine, Virology, Health care, Medical research, Influenza research

By contrast, most countries in Africa have administered no vaccine doses at all.

Key Points: 
  • By contrast, most countries in Africa have administered no vaccine doses at all.
  • The scale of vaccine hoarding is most starkly apparent in the vast quantities of doses some countries have locked up in production contracts in excess of what is needed to vaccinate their entire populations.
  • What use is it to vaccinate only the rich countries while new, more deadly variants spring up in developing countries?
  • We must set aside patent monopolies, increase vaccine funding and call on countries to do everything they can to cooperate and coordinate their efforts.

NTHU Research Team Develops Groundbreaking Influenza Vaccine

Retrieved on: 
Friday, March 12, 2021
Research, Medical Supplies, Infectious diseases, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Vaccination, Medical specialties, Health, Vaccines, Influenza vaccines, Medical research, Live attenuated influenza vaccine, Swine flu pandemic, Vaccine, Influenza, COVID-19 vaccine, Influenza research

With this situation in mind, a research team led by Professor Wu Suh-Chin of the Department of Medical Science has developed a vaccine providing protection against all strains of influenza.

Key Points: 
  • With this situation in mind, a research team led by Professor Wu Suh-Chin of the Department of Medical Science has developed a vaccine providing protection against all strains of influenza.
  • View the full release here: https://www.businesswire.com/news/home/20210312005008/en/
    A research team led by Professor Wu Suh-Chin of the Department of Medical Science has developed a mucosal vaccine providing protection against all strains of influenza, and is currently planning to develop a mucosal COVID-19 vaccine.
  • Since influenza viruses are mainly transmitted through the respiratory tract, Wu's team invented a nasal spray influenza vaccine that is more effective than an injection.
  • Spurred on by the encouraging results, the team is currently planning to develop a mucosal vaccine providing protection against COVID-19.

Nexus Pharmaceuticals Stands Ready to Support Efforts to Increase Vaccine Manufacturing

Retrieved on: 
Thursday, February 11, 2021
Other Manufacturing, Infectious diseases, Hospitals, Public policy, Government, Manufacturing, Other Health, White House, Federal Government, General Health, Pharmaceutical, Health, Medical research, Medicine, Health sciences, Medical specialties, Vaccination, Vaccines, COVID-19 vaccine, Vaccine, Deployment of COVID-19 vaccines, Influenza research

Nexus Pharmaceuticals supports the Biden-Harris administrations decision to invoke the Defense Production Act (DPA) in order to boost supplies needed for COVID-19 vaccine production and for at-home virus test kits.

Key Points: 
  • Nexus Pharmaceuticals supports the Biden-Harris administrations decision to invoke the Defense Production Act (DPA) in order to boost supplies needed for COVID-19 vaccine production and for at-home virus test kits.
  • View the full release here: https://www.businesswire.com/news/home/20210211005846/en/
    As one of the nations leading specialty drug developers, Nexus stands ready to serve and support any efforts to increase vaccine manufacturing.
  • Due to the brand-new manufacturing capacity of our state-of-the-art facility in Wisconsin, Nexus will be able to maintain the production of existing products and simultaneously begin manufacturing vaccines.
  • Given our unique ability to increase vaccine manufacturing for any of the five vaccine developers, we stand ready to assist any of the vaccine developers and the United States government in their quest to ramp up vaccine manufacturing.

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

Coronavirus (COVID-19) Update: FDA Holds Advisory Committee Meeting to Discuss Authorization of COVID-19 Vaccine Candidate as Part of Agency's Review of Safety and Effectiveness Data

Retrieved on: 
Thursday, December 10, 2020
Health sciences, Health, Medicine, COVID-19 vaccine, Medical research, Vaccines, Food and Drug Administration, Clinical trial, Vaccine, Influenza research, Influenza vaccine

The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.

Key Points: 
  • The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.
  • These data include, but are not limited to clinical trial data, non-clinical data on the development of the vaccine in the lab, and manufacturing data on how the vaccine is made.
  • FDA career officials have been reviewing the data and information ahead of the public advisory committee meeting to ensure a robust discussion with the independent experts.
  • In this time of great urgency, FDA staff feel the responsibility to move as quickly as possible through the review process.